You have changed your country from  to  . Please be aware that this will change the currency in the purchasing process.

Anti-Sclerostin antibody - Aminoterminal end (ab63097)

CodeSizePriceAbpointsAvailability
    
 
  • -

  •   
  •   
  •   
  •  

  •  
  •  
  •  

  •  
Updating...

Reassurance, Refunds & Replacements

If your product does not perform as described on this datasheet, we will refund or replace your product...

Read our guarantee »

Overview

Product name

Anti-Sclerostin antibody - Aminoterminal end
See all Sclerostin products (6) ...

Description

Rabbit polyclonal to Sclerostin - Aminoterminal end

Tested applications

WB, ELISA, IHC-Pmore details

Cross reactivity

Reacts with

Mouse, Sheep, Human

Immunogen

KLH conjugated synthetic peptide selected from the N terminal region of human Sclerostin.

Positive control

WB: Mouse liver tissue lysate IHC-P: Human breast carcinoma tissue

Properties

Form

Liquid

Storage instructions

Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C or -80°C. Avoid repeated freeze / thaw cycles.

Storage buffer

Preservative: 0.09% Sodium Azide
Constituents: PBS

Concentration

Concentration information loading...

Purity

Protein A purified

Clonality

Polyclonal

Isotype

IgG

  • Western blot - Sclerostin antibody - Aminoterminal end (ab63097)Western blot - Sclerostin antibody - Aminoterminal end (ab63097) image (enlarge)

  • Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Sclerostin antibody - Aminoterminal end (ab63097)Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Sclerostin antibody - Aminoterminal end (ab63097) image (enlarge)

Applications

Show applications key

Our Abpromise guarantee covers the use of ab63097 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Target

Function

Negative regulator of bone growth.

Tissue specificity

Widely expressed at low levels with highest levels in bone, cartilage, kidney, liver, bone marrow and primary osteeoblasts differentiated for 21 days.

Involvement in disease

Defects in SOST are the cause of sclerosteosis (SOST) [MIM:269500]; also known as cortical hyperostosis with syndactyly. SOST is an autosomal recessive sclerosing bone dysplasia characterized by a generalized hyperostosis and sclerosis leading to a markedly thickened skull, with mandible, ribs, clavicles and all long bones also being affected. Due to narrowing of the foramina of the cranial nerves, facial nerve palsy, hearing loss and atrophy of the optic nerves can occur. Sclerosteosis is clinically and radiologically very similar to van Buchem disease, mainly differentiated by hand malformations and a large stature in sclerosteosis patients.
Note=A 52 kb deletion downstream of SOST results in SOST transcription suppression and is a cause of van Buchem disease (VBCH) [MIM:239100]; also known as hyperostosis corticalis generalisata. VBCH is an autosomal recessive sclerosing bone dysplasia characterized by endosteal hyperostosis of the mandible, skull, ribs, clavicles, and diaphyses of the long bones. Affected patients present a symmetrically increased thickness of bones, most frequently found as an enlarged jawbone, but also an enlargement of the skull, ribs, diaphysis of long bones, as well as tubular bones of hands and feet. The clinical consequence of increased thickness of the skull include facial nerve palsy causing hearing loss, visual problems, neurological pain, and, very rarely, blindness as a consequence of optic atrophy. Serum alkaline phosphatase levels are elevated.

Sequence similarities

Belongs to the sclerostin family.
Contains 1 CTCK (C-terminal cystine knot-like) domain.

Cellular localization

Secreted.

Target information above from: UniProt accessionQ9BQB4 The UniProt Consortium
The Universal Protein Resource (UniProt) in 2010
Nucleic Acids Res. 38:D142-D148 (2010).

Information by UniProt

Alternative names

  • BEER antibody
  • Cortical hyperostosis with syndactyly antibody
  • Sclerosteosis antibody
  • Sclerostin antibody
  • SOST antibody
  • SOST_HUMAN antibody
  • VBCH antibody
see all

Anti-Sclerostin antibody - Aminoterminal end images:

  Western blot - Sclerostin antibody - Aminoterminal end (ab63097)

Western blot - Sclerostin antibody - Aminoterminal end (ab63097)

Anti-Sclerostin antibody - Aminoterminal end (ab63097) at 1/60 dilution + mouse liver tissue lysates at 35 µg

Predicted band size : 24 kDa
Observed band size : 24 kDa
Additional bands at : 55 kDa. We are unsure as to the identity of these extra bands.

  Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Sclerostin antibody - Aminoterminal end (ab63097)

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Sclerostin antibody - Aminoterminal end (ab63097)

Immunohistochemical analysis of sclerostin expression in paraffin embedded formalin fixed human breast carcinoma tissue section using 1/10 ab63097, followed by HRP conjugated secondary antibody step and DAB staining.

References for Anti-Sclerostin antibody - Aminoterminal end (ab63097)

This product has been referenced in:

  • Cohen-Kfir E  et al. Sirt1 is a regulator of bone mass and a repressor of Sost encoding for sclerostin, a bone formation inhibitor. Endocrinology 152:4514-24 (2011). Mouse.Read more (PubMed: 21952235) »
  • Mardaryev AN  et al. Micro-RNA-31 controls hair cycle-associated changes in gene expression programs of the skin and hair follicle. FASEB J 24:3869-81 (2010). WB; Mouse.Read more (PubMed: 20522784) »

See all 2 publications for this product

Publishing research using ab63097? Please let us know so that we can cite the reference in this datasheet

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"